^
    Back
    Association details:
    Biomarker:TP53 wild-type
    Cancer:Merkel Cell Carcinoma
    Drug:milademetan (RAIN-32) (MDM2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    JCI Insight
    Title:

    Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma

    Published date:
    07/08/2022
    Excerpt:
    Milademetan reduced cell viability of WT p53 MCC cell lines and triggered a rapid and sustained p53 response. Milademetan showed a dose-dependent inhibition of tumor growth in MKL-1 xenograft and patient-derived xenograft models. Here, along with preclinical data for the efficacy of milademetan in WT p53 MCC tumors...
    DOI:
    10.1172/jci.insight.160513